Quantcast

Latest Lupus erythematosus Stories

2010-08-09 07:00:00

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor...

2010-07-29 07:30:00

HAYWARD, Calif., July 29 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue,...

2010-07-12 08:33:00

Findings Could Lead to Lower Doses of Medication for Lupus Patients, Reducing Serious Side Effects DALLAS, July 12 /PRNewswire-USNewswire/ -- Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute (BRI) in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide. Currently, those with lupus and other autoimmune diseases, commonly treat...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM(TM), suggest promising results of epratuzumab in patients with SLE. EMBLEM(TM) was a 12-week,...

2010-06-10 13:42:00

HAYWARD, Calif., June 10 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has updated its Lupus Scientific Advisory Board. A-623 is Anthera's Phase 2b compound being developed as a treatment for systemic lupus erythematosus (SLE). "Anthera is developing a promising therapeutic for Lupus, a condition in great need of...

2010-02-01 07:00:00

WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market. If approved, Benlysta will be the first agent to launch for systemic lupus erythematosus in...

2010-01-28 11:46:08

Largest US study to date finds mortality outcomes improving A recent study by researchers from the Cleveland Clinic found that the overall mortality rate in the U.S. for all pediatric patients with rheumatic diseases was not worse than the age and sex-adjusted population. Furthermore, mortality rates were significantly lower than reported in previous studies of rheumatic diseases and conditions that are associated with increased mortality. Details of the study appear in the February issue of...

2010-01-22 13:37:00

New report resulting from Lupus Research Institute's congressional advocacy describes state of lupus research, impact of disease, and barriers to care NEW YORK, Jan. 22 /PRNewswire-USNewswire/ -- A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical...

2009-11-01 06:06:01

Contrary to previous studies, lupus patients who receive kidney transplants rarely develop lupus nephritis Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. The findings indicate that having lupus should not keep individuals from seeking a kidney...

2009-08-11 07:00:00

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018. The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related